
Jul 24, 2026
NewAmsterdam Pharma and Menarini Receive Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe in Europe
NewAmsterdam Pharma and Menarini have received a favorable opinion from the CHMP regarding their cholesterol-lowering treatments, obicetrapib and its combination with ezetimibe, paving the way for potential commercialization in Europe.This positive recommendation is founded on robust data from Phase 3 clinical trials—BROADWAY, BROOKLYN, and TANDEM—demonstrating significant reductions in low-density lipoprotein cholesterol (LDL-C). Specifically, obicetrapib monotherapy showed up to a 40% decrease









